

NCT ID	NCT03365882
Title	S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Phase	Phase 2
Date Added	2017-12-07
Location	Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta
Tags	MSS/ MMRp

NCT ID	NCT03657641
Title	Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2018-09-05
Location	California, United States Florida, United States

Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03296137
Title	Adoptive Cell Therapy Across Cancer Diagnoses
Phase	Phase 1/Phase 2
Date Added	2017-09-28
Location	Denmark
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03599765
Title	Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor
Phase	Phase 2
Date Added	2018-07-26
Location	Arizona, United States Arkansas, United States Hawaii, United States Michigan, United States New Jersey, United States Ohio, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03568058
Title	Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Phase	Phase 1
Date Added	2018-06-26
Location	California, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab, personalized vaccine, Keytruda
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04003792
Title	Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
Phase	Phase 2
Date Added	2019-07-01
Location	Israel

Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab, FOLFIRI Protocol, oxaliplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02988960
Title	A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Phase	Phase 1
Date Added	2016-12-12
Location	California, United States Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Australia Canada France Japan Korea, Republic of Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	ABBV-181, ABBV-927, Opdivo
Tags	MSS/ MMRp
NCT ID	NCT04426669
Title	A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Phase	Phase 1, Phase 2
Date Added	2020-06-11
Location	Minnesota, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL)
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04062721
Title	Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases
Phase	Phase 1
Date Added	2019-08-20
Location	France
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Chemotherapy, In situ immunotherapy
Tags	MSS/ MMRp
NCT ID	NCT04895709
Title	A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase	Phase 1, Phase 2
Date Added	2021-05-20
Location	California, United States Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Australia Canada Germany Israel Italy Japan Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	BMS-936558-01, BMS-986340
Tags	MSI-H/ MMRd, MSS/ MMRp